-
Swedish police identify 17-year-old girl as victim in school sword attack
-
Yamaguchi to face An in hunt for fourth badminton world crown
-
Carrick keeps calm despite Man Utd misery, Sage beaten in first game as Palace boss
-
Norris clinches pole for Dutch GP
-
France to deliver interceptor missiles to Ukraine after new Russian strikes
-
Norris clinches pole for Dutch Grand Prix
-
Serena Williams and Alcaraz unite in US Open mixed doubles
-
Pope Leo calls for courage in Rimini visit after stop in tiny San Marino
-
Macron pledges air defence as 13 killed in Russia, Ukraine strikes
-
Man Utd must learn from 'frustrating' defeat at Hull: Carrick
-
DR Congo capital wary of Ebola nightmare
-
Yamaguchi on course for fourth badminton world crown
-
Swedish police name 17-year-old girl as victim in school sword attack
-
Man Utd humiliated by Hull in dismal start to Premier League season
-
South Korea sends first container ship through Arctic route
-
Anthropic market debut could break SpaceX IPO record: media
-
Trescothick eager to keep England job despite Hussey approach
-
Pope's 'couturier of the sacred' fueled by faith
-
Indonesia deploys hundreds of soldiers to tackle Borneo fires
-
Duplantis locked in on 'grinding' for big bars
-
The last lap: Fans, drivers bid fond farewell to Dutch GP
-
Stokes says decision to leave Headingley off Ashes roster 'shambolic'
-
Silesia Diamond League: four events to watch
-
New arrival Rodri to miss Elche opener: Barca's Flick
-
Russell wins Dutch GP sprint race, Antonelli fourth
-
Atletico's Alvarez to return against Villarreal: Simeone
-
Mercedes driver George Russell wins Dutch GP sprint race
-
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
-
Ukraine strikes kill two children after Russia's deadly mall attack
-
Former envoys urge joint French, UK action on Palestinian territories
-
Pope visits San Marino, before addressing Italian political gathering
-
Australia lead by 101 in 2nd Bangladesh Test as 18 wickets fall on day one
-
Trump tariffs heap up as Canada tries to curb US reliance
-
'Aura' battles leap from social media to Latin America streets
-
Australia lose three wickets after skittling Bangladesh for 64
-
US, Canada fail to reach trade pact to avert Trump tariffs
-
Bangladesh all out for 64 in 2nd Test after Starc masterclass
-
Sudan farms lie barren as El Nino leaves Nile banks dry
-
Odyssey effect: stars sell Greece to a new wave of US tourists
-
Arctic shipping a daunting prospect in hotly contested region
-
South Korea to send first container ship through Arctic route
-
In US, rare earths extracted from coal mine wastewater
-
Starc takes 5-11 to leave Bangladesh reeling in 2nd Test
-
Nakashima pounds Fritz, Bejlek beats Keys in Cincinnati upsets
-
Injured Rune withdraws from US Open
-
Canadian negotiator says 'more work to do' on US trade deal
-
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET
-
Nakashima knocks out Fritz to reach Cincinnati semi-finals
-
'Solid' Clark takes solo lead at BMW Championship
-
Ukraine says 'cynical' Russian strike on shopping centre killed 16
Featured
Last news
Medical Care Technologies (OTC PINK:MDCE) Provides Initial Overview of Melanoma Scan Beta User Experience and Interface Design
Company highlights streamlined body-map tracking and image management features designed to support long-term skin monitoring workflows
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress, and advance Gemini as a treatment for AKI. Drawing on their collective expertise, the board will help shape the most effective study design to address the significant unmet medical need in AKI and ultimately improve patient outcomes.
They're Calling It Hemp, Cannabis Medicine. Pesticides, Mycotoxins, Fraudulent Lab Reports? And Medicare Is Now Reimbursing It
Pesticides. Mycotoxins. Fraudulent Lab Reports. Forged Certificates of Analysis. This Is the State-Licensed Cannabis and Hemp Supply Chain the Courts and DEA Just Handed a Federal Registration Pathway - While the FDA Commissioner Looked Away and Judge McFadden Said Nobody Has Standing to Complain.
RF Industries to Report Second Quarter Results on June 15
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / RF Industries, Ltd, (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced that it will release its second quarter fiscal year 2026 financial results after the close of the market on Monday, June 15, 2026.
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA aloneIntismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345])
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.
American Rebel Holdings, Inc. (OTC:AREB) Proudly Announces American Rebel Light Beer - America's Patriotic Beer - Is Now Available in Central Florida Through Wayne Densch, Inc.
Wayne Densch - Central Florida's #1 Beer Distributor for Over 64 Years - Launched American Rebel Light Beer on May 1, bringing 6-Pack 16 oz Cans and 12-Pack 12 oz Cans to the Central Florida Market Following a February American Rebel Tour Bus Meeting and February 15 Contract SigningWayne Densch Has Featured American Rebel Light Beer as a New Product on Its Corporate Website and Facebook Page; Patriots Across Central Florida Can Now Raise a Cold One for God, Country, and the Constitution
Black Book to Release Highly Anticipated 2026 Vendor-Agnostic RCM KPI Results Ahead of HFMA Annual Conference 2026
Independent qualitative KPIs across 48 RCM categories will help healthcare buyers prove platform performance before purchase\, measuring user experience, functional outcomes, workflow execution, process gains, reimbursement impact, problem-solving value, automation readiness, and AI governance, without vendor influence, sponsorship, subscriptions, or pay-to-participate models.
Wellgistics Health Provides Mid-Year 2026 Corporate Outlook
Focus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progressRecent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing conditionRecent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities.Recent lock-up agreement to limit shares available for sale into the marketExercise of warrants embedded in recent financing would provide funding through 2029
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.
Med-X Secures Strategic Relationship with Main Line Brands, Franchisor of Mosquito Authority and Pest Authority, One of the Largest Pest Control Franchise Systems in North America
Nature-Cide X2 Plus Selected as Preferred All-Natural SolutionAs Customer Demand Trends Toward Natural Pest Control Solutions, Mosquito Authority / Pest Authority Launches Company-Wide Initiative to Integrate Nature-Cide X2 Plus; Med-X to Support Rollout with Marketing, Advertising and Franchisee Education
Who Does the Best Mommy Makeover in Seattle?
The Best Mommy Makeover In Seattle Is By Dr. Javad Sajan
Who Does the Best Liposuction in Sarasota?
The Best Liposuction Is Done By Dr. Alberico Sessa
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation
GERSTEL Strengthens Global Scientific Engagement with Bioz to Unlock Publication-Driven Insights Across Its Product Portfolio
PALO ALTO, CA / ACCESS Newswire / June 1, 2026 / Bioz, Inc., the platform converting publications into product credibility, announced its collaboration with GERSTEL, is a member of the Velaris family, which includes more than seven brands and is home to some of the world's leading laboratory automation companies, supported by the global investment firm Battery Ventures. GERSTEL is enhancing how researchers discover and engage with publication-backed validation through the implementation of Bioz Badges across its website.
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 01
Purchase of own shares
Paris celebrates football triumph amid riot recriminations
The French capital laid out a red, white and blue carpet Sunday for Paris Saint-Germain players to mark their second straight Champions League title, amid bitter recriminations after hundreds of people were arrested and dozens of police hurt in a night of unrest.
Paris Saint-Germain players celebrate amid riot recriminations
The French capital laid on a hero's welcome Sunday for Paris Saint-Germain players to mark their second straight Champions League title, amid bitter recriminations after hundreds of people were arrested and dozens of police hurt in a night of unrest across the country.
Paris prepares hero's welcome for PSG Champions League winners under heavy security
Paris prepared a hero's welcome for Paris Saint-Germain players who won their second consecutive Champions League title with celebrations planned in the capital under heavy security after a night of revelry marred by unrest.
Two decades later, impacts from Indonesia mud volcano linger
Harwati clasped her hands and offered a prayer on the edge of a sludge lake on the Indonesian island of Java, as dozen of residents gathered to mark two decades since mud volcano eruptions began displacing thousands.
Australian researchers teach brain cells to play 'Doom'
Australian researchers have trained lab-grown brain cells on a silicon computer chip to play the nineties shooter "Doom" and say they are just scratching the surface of what the neurons could be capable of doing.
'Totally hooked': Hong Kong targets claw machine addiction
Claw machine lover Neiki Lee carefully lowers the metal jaws of a crane with a joystick into a pool of prizes, only to have the small toy slip from its clutches again and again.
Will State Marijuana Operators Get a Federal Green Light Before DEA Resolves MMJ's Seven-Year Wait?
"One DEA Schedule I laboratory registration approved. FDA INDs granted. Orphan Drug Designation awarded. Yet the cultivation application remains unresolved as patients continue to wait. This is responsible drug policy?" stated Duane Boise, CEO MMJ International Holdings.Anne Milgram is gone, and most of the architects of pharmaceutical obstruction have retired. As the June 29 rescheduling hearing approaches, the DEA must answer for a decade of systematic patient abandonment.
Trump admin walks back recent Green Card announcement
The Trump administration has walked back its announcement that non-citizens seeking permanent US residency, commonly called a Green Card, would need to return to their home country to apply, The New York Times reported.
Heatwave makes conditions 'inhumane', say inmates at overcrowded Paris suburb prison
A damp towel hangs from a barred window, a fan churns the muggy air: Inmates at the overcrowded Villepinte prison outside Paris say enduring a heatwave that has stifled France in recent days in cramped cells is "inhumane".
Canadian poison seller pleads guilty to aiding suicides, avoids murder trial
The Canadian man who sold poison to distressed people worldwide pleaded guilty on Friday to 14 counts of aiding suicide but avoided a murder trial, an outcome one victim's father branded "a disgrace."
MMJ ET AL PREPARES APPEAL CMS HEMP PROGRAM: How Can a Company With a Manufactured Pharmaceutical Soft Gel Be Told It Has "No Product"?
JUDGE McFADDEN SAID MMJ HAS "NO PRODUCT." THE RECORD SAYS OTHERWISE.How Can a Company With FDA INDs, Orphan Drug Designation, Manufactured Soft gel Capsules, and Reproducible Chemistry Be Described as Having "No Product"? asked Duane Boise, CEO MMJ International Holdings.
Canadian poison seller pleads guilty to aiding suicides
The Canadian man who helped scores of people worldwide kill themselves by selling them poison pleaded guilty on Friday to 14 counts of aiding suicide, as prosecutors said they will withdraw murder charges.
German ex-minister faces perjury charges over failed car toll plan
A former German transport minister faces a perjury trial related to a failed scheme to charge foreign motorists highway tolls, a debacle that cost the government hundreds of millions of euros.
Blue Origin rocket explodes on launch pad
Blue Origin's New Glenn rocket exploded during a test Thursday on the launch pad in Cape Canaveral, Florida, though officials said no injuries were reported from the incident.
Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC0, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences company and parent of the Vanta premium longevity brand, announces a proposed non-brokered private placement financing (the "Private Placement"), consisting of the issuance of an aggregate of up to 2,500,000 units of the Company (each, a "Unit"), at a price of $1.00 per Unit for aggregate gross proceeds of up to $2,500,000.
The Fresh Factory Reports Q1 2026 Financial Results with 17% Billed Revenue Growth, Completes New Facility Retrofit
The Company reported a record quarterly billed revenue of $12.5M (CAD $17.8M) in Q1 2026, representing a YoY increase of 17% from Q1 2025.The Company achieved positive EBITDA of $0.3M (CAD $0.4M) and Adjusted EBITDA of $0.5M (CAD $0.7M) in Q1 2026, despite incremental costs associated with the ramp-up of its new manufacturing facility.The Company completed the retrofit and commenced operations at its newly leased 154,000-square-foot manufacturing facility in the southwest suburbs of Chicago, expanding production capacity for future growth.The Company completed a $3.0M ($4.3M) private placement in January 2026, strengthening its balance sheet and supporting its expansion strategy.